A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors

BACKGROUND: Several programmed cell death ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) antibodies have been approved for cancer treatment worldwide. Their pharmacokinetic and pharmacodynamic characteristics have been reported mainly in western countries, but related data in Chinese patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiao‐Li, Ren, Chao, Wang, Feng‐Hua, Zhang, Yang, Zhao, Hong‐Yun, Zou, Ben‐Yan, Wang, Zhi‐Qiang, Qiu, Miao‐Zhen, Zhang, Dong‐Sheng, Luo, Hui‐Yan, Wang, Feng, Yao, Sheng, Xu, Rui‐Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427305/
https://www.ncbi.nlm.nih.gov/pubmed/32589350
http://dx.doi.org/10.1002/cac2.12068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427305/
https://www.ncbi.nlm.nih.gov/pubmed/32589350
http://dx.doi.org/10.1002/cac2.12068

Ejemplares similares